Follow
Craig Hofmeister
Craig Hofmeister
Associate professor, Emory University
Verified email at emory.edu
Title
Cited by
Cited by
Year
Initial genome sequencing and analysis of multiple myeloma
MA Chapman, MS Lawrence, JJ Keats, K Cibulskis, C Sougnez, ...
Nature 471 (7339), 467-472, 2011
16872011
Lenalidomide after stem-cell transplantation for multiple myeloma
PL McCarthy, K Owzar, CC Hofmeister, DD Hurd, H Hassoun, ...
New England Journal of Medicine 366 (19), 1770-1781, 2012
13172012
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
JG Lohr, P Stojanov, SL Carter, P Cruz-Gordillo, MS Lawrence, D Auclair, ...
Cancer cell 25 (1), 91-101, 2014
10892014
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody
DM Benson Jr, CE Bakan, A Mishra, CC Hofmeister, Y Efebera, ...
Blood, The Journal of the American Society of Hematology 116 (13), 2286-2294, 2010
9362010
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J Chu, Y Deng, DM Benson, S He, T Hughes, J Zhang, Y Peng, H Mao, ...
Leukemia 28 (4), 917-927, 2014
4642014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, ...
Blood, The Journal of the American Society of Hematology 123 (12), 1826-1832, 2014
4442014
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
SM Collins, CE Bakan, GD Swartzel, CC Hofmeister, YA Efebera, H Kwon, ...
Cancer Immunology, Immunotherapy 62, 1841-1849, 2013
3372013
Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche
CC Hofmeister, J Zhang, KL Knight, P Le, PJ Stiff
Bone marrow transplantation 39 (1), 11-23, 2007
3152007
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
DM Benson Jr, CC Hofmeister, S Padmanabhan, A Suvannasankha, ...
Blood, The Journal of the American Society of Hematology 120 (22), 4324-4333, 2012
2642012
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
DM Benson Jr, CE Bakan, S Zhang, SM Collins, J Liang, S Srivastava, ...
Blood, The Journal of the American Society of Hematology 118 (24), 6387-6391, 2011
2282011
Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology
SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ...
Journal of the National Comprehensive Cancer Network 15 (2), 230-269, 2017
2222017
Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma
NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, ...
Journal of Clinical Oncology 38 (17), 1928, 2020
1922020
A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma
DM Benson Jr, AD Cohen, S Jagannath, NC Munshi, G Spitzer, ...
Clinical Cancer Research 21 (18), 4055-4061, 2015
1852015
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a …
SA Holstein, SH Jung, PG Richardson, CC Hofmeister, DD Hurd, ...
The Lancet Haematology 4 (9), e431-e442, 2017
1602017
NCCN guidelines insights: multiple myeloma, version 3.2018
SK Kumar, NS Callander, M Alsina, D Atanackovic, JS Biermann, ...
Journal of the National Comprehensive Cancer Network 16 (1), 11-20, 2018
1512018
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
F Pichiorri, D Palmieri, L De Luca, J Consiglio, J You, A Rocci, T Talabere, ...
Journal of Experimental Medicine 210 (5), 951-968, 2013
1502013
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, ...
Blood Cancer Journal 9 (12), 94, 2019
1462019
Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy
JK Bailur, SS McCachren, DB Doxie, M Shrestha, K Pendleton, AK Nooka, ...
JCI insight 4 (11), 2019
1342019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, ...
Nature communications 10 (1), 1911, 2019
1312019
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
C Chen, D Siegel, M Gutierrez, M Jacoby, CC Hofmeister, N Gabrail, ...
Blood, The Journal of the American Society of Hematology 131 (8), 855-863, 2018
1312018
The system can't perform the operation now. Try again later.
Articles 1–20